Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

被引:124
|
作者
Zimetbaum, Peter J. [1 ]
Thosani, Amit
Yu, Hsing-Ting [2 ]
Xiong, Yan [2 ]
Lin, Jay [3 ]
Kothawala, Prajesh [2 ]
Emons, Matthew [2 ]
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Cerner LifeSci, Beverly Hills, CA USA
[3] Sanofi Aventis, Bridgewater, NJ USA
关键词
Anticoagulation; Atrial fibrillation; Atrial flutter; Stroke risk; Warfarin; RHYTHM-CONTROL; ORAL ANTICOAGULATION; MANAGEMENT; THERAPY; PREVENTION; GUIDELINES; IMPACT;
D O I
10.1016/j.amjmed.2009.11.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Clinical guidelines for the management of atrial fibrillation and atrial flutter provide recommendations for anticoagulation based on patients' overall risk of stroke. To determine the real-world compliance of physicians with these recommendations, we conducted a retrospective cohort study examining the utilization of warfarin in atrial fibrillation/flutter patients by stroke risk level. METHODS: Patients with a qualifying atrial fibrillation/flutter diagnosis during >= 18 months' continuous enrollment between January 2003 and September 2007, and with >= 6 months' eligibility after the first atrial fibrillation/flutter diagnosis, were identified from the US Market Scan database (Thomson Reuters, New York, NY). Warfarin use within 30 days of the first diagnosis was assessed according to stroke risk, estimated using the Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (CHADS(2)) score. RESULTS: Of 171,393 patients included in the analysis, 20.0% had a CHADS(2) score of 0 (low risk), 61.6% a score of 1-2 (moderate risk), and 18.4% a score of 3-6 (high risk). Warfarin, recommended for high stroke-risk patients, was given to only 42.1% of those with a CHADS(2) score of 3-6. A similar percentage of patients with moderate (43.5%) or low stroke risk (40.1%) received warfarin. Only 29.6% of high-risk, 33.3% of moderate-risk, and 34.1% of low-risk patients who were started on warfarin received. uninterrupted therapy for 6 months following their initial prescription. CONCLUSIONS: These data suggest that guideline recommendations that anticoagulation should be provided in accordance with stroke risk in atrial fibrillation patients are not routinely followed in clinical practice. The causes and clinical implications of under-utilization of anticoagulation in atrial fibrillation patients with high stroke risk warrant further study. (c) 2010 Elsevier Inc. All rights reserved. The American Journal of Medicine (2010) 123, 446-453
引用
收藏
页码:446 / 453
页数:8
相关论文
共 50 条
  • [1] Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis
    Shah, Mitesh
    Tsadok, Meytal Avgil
    Jackevicius, Cynthia A.
    Essebag, Vidal
    Eisenberg, Mark J.
    Rahme, Elham
    Humphries, Karin H.
    Tu, Jack V.
    Behlouli, Hassan
    Guo, Helen
    Pilote, Louise
    CIRCULATION, 2014, 129 (11) : 1196 - 1203
  • [2] Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis
    Lei, Hong
    Yu, Li-Ting
    Wang, Wei-Ning
    Zhang, Shun-Guo
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [3] Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin A Systematic Review and Meta-analysis
    Albertsen, Ida Ehlers
    Rasmussen, Lars Hvilsted
    Overvad, Thure Filskov
    Graungaard, Tina
    Larsen, Torben Bjerregaard
    Lip, Gregory Y. H.
    STROKE, 2013, 44 (05) : 1329 - +
  • [4] Additional risk factors in atrial fibrillation patients not receiving warfarin
    Wensley, S
    Keir, S
    Caine, S
    Mac Mahon, M
    AGE AND AGEING, 1999, 28 (04) : 355 - 357
  • [5] Periprocedural Stroke Risk in Patients Undergoing Catheter Ablation for Atrial Fibrillation on Uninterrupted Warfarin
    Page, Stephen P.
    Herring, Neil
    Hunter, Ross J.
    Withycombe, Emma
    Lovell, Matthew
    Wali, G.
    Betts, Timothy R.
    Bashir, Yaver
    Dhinoja, Mehul
    Earley, Mark J.
    Sporton, Simon C.
    Rajappan, Kim
    Schilling, Richard J.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2014, 25 (06) : 585 - 590
  • [6] Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea
    Lee, Iyn-Hyang
    Kim, Hyunah
    Je, Nam Kyung
    JOURNAL OF CARDIOLOGY, 2015, 66 (5-6) : 475 - 481
  • [7] Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation
    Kai, Brandon
    Bogorad, Yuliya
    Nguyen, Leigh-Anh N.
    Yang, Su-Jau
    Chen, Wansu
    Spencer, Hillard T.
    Shen, Albert Y. -J.
    Lee, Ming-Sum
    HEART RHYTHM, 2017, 14 (05) : 645 - 651
  • [8] Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention
    Hirano, Teruyuki
    Kaneko, Hirokazu
    Mishina, Sari
    Wang, Feng
    Morita, Satoshi
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (10) : 2102 - 2110
  • [9] Warfarin persistence among stroke patients with atrial fibrillation
    Bjorck, Fredrik
    Renlund, Henrik
    Svensson, Peter J.
    Sjalander, Anders
    THROMBOSIS RESEARCH, 2015, 136 (04) : 744 - 748
  • [10] Warfarin Discontinuation After Starting Warfarin for Atrial Fibrillation
    Fang, Margaret C.
    Go, Alan S.
    Chang, Yuchiao
    Borowsky, Leila H.
    Pomernacki, Niela K.
    Udaltsova, Natalia
    Singer, Daniel E.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (06): : 624 - 631